Abstract
Objectives Recent observations in systemic Juvenile Idiopathic Arthritis (sJIA) suggest an increasing incidence of high-mortality interstitial lung disease (ILD), characterized pathologically by a variant of pulmonary alveolar proteinosis (PAP). The co-occurrence of macrophage activation syndrome (MAS) and PAP in sJIA suggested a shared pathology, but features of drug reaction such as anaphylaxis, rashes, and eosinophilia are also common in these patients. We sought to investigate immunopathology and identify biomarkers of this lung disease.
Methods We used SOMAscan to measure >1300 analytes in serum samples from healthy controls and patients with sJIA-PAP, sJIA, sJIA-MAS, and other associated diseases, and verified selected findings by ELISA and lung immunostaining. Because a sample’s proteome may reflect multiple states (SJIA, MAS, SJIA-PAP), we used linear regression modeling to identify subsets of altered proteins associated with each state.
Results Markers identified for sJIA, including SAA, S100A9, and S100A12, were consistent with previous reports. Proteome alterations in sJIA and MAS overlapped substantially, including new findings of heat shock proteins and glycolytic enzymes. sJIA, MAS, and sJIA-PAP shared elevation of IL-18. Importantly, we identified a unique sJIA-PAP signature whose expression was independent of sJIA-MAS activity. Key proteins were ICAM5 and MMP7, previously observed markers of fibrotic ILD. Immunohistochemistry showed expression of these proteins in sJIA-PAP lung, supporting a pulmonary source. The eosinophil chemoattractant CCL11 was elevated in sJIA-PAP, but not sJIA/MAS or other PAP.
Conclusions We found novel circulating proteins associated specifically with sJIA, sJIA/MAS and sJIA-PAP. Select biomarkers, such as ICAM5, could aid in early detection and management of sJIA-PAP.
Key Messages
Pulmonary Alveolar Proteinosis (PAP) occurring in the setting of Systemic Juvenile Idiopathic Arthritis (sJIA) is an increasingly-noted, dangerous condition that has been associated with Macrophage Activation Syndrome (MAS).
We evaluated >1300 serum proteins by aptamer array, verifying and localizing key proteins, and identified novel pathways associated with MAS (HSPs, glycolysis), candidate pathways/proteins associated with PAP in sJIA (e.g., ICAM5, MMP7, and type 2 chemokines), and divergence of the sJIA/MAS and sJIA-PAP proteomes.
This analysis supports the evaluation of novel pathways in MAS, the validation of screening/monitoring biomarkers in sJIA-PAP, and the management of PAP as a disease process enmeshed with, but distinct from, sJIA and MAS.
Competing Interest Statement
VS reports personal fees from Novartis, grants from Novartis, outside the submitted work. SC reports grants from Systemic JIA Foundation, grants from NICHD, grants from RK Mellon Institute, during the conduct of the study; grants from AB2Bio, Ltd., other from Simcha Therapeutics, grants from IMMvention Therapeutix, outside the submitted work. RG-M reports grants from Systemic JIA Foundation during the conduct of the study; grants from Lilly, grants from SOBI outside the submitted work. EM reports grants from Lucille Packard Foundation for Children Health, grants from CARRA-Arthritis Foundation, during the conduct of the study; grants from Novartis, grants from GSK, outside the submitted work. PK reports personal fees and other from Inflammatix, Inc., personal fees from Cepheid, outside the submitted work. GS reports personal fees from Novartis, personal fees from SOBI, outside the submitted work. GD reports personal fees from Novartis Pharmaceuticals, outside the submitted work. AG reports grants and personal fees from Sobi, grants and personal fees from Novartis, grants and personal fees from AB2Bio, during the conduct of the study.
Funding Statement
The SOMAscan assay was supported by a grant to the Intramural Research Program of the NIAID from the Systemic JIA Foundation. AAdJ and RGM were supported by the NIAID intramural research program. GC is an Eli Lilly Fellow of the Life Science Research Foundation. SJ is supported by Dean Postdoctoral Fellowship, School of Medicine, Stanford. CM and EDM were supported by NIAMS R01 AR066551, AR061297 and Arthritis Foundation Great West Region Arthritis Center of Excellence; VS and EDM were supported by the Lucille Packard Foundation for Children Health and a Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation grant. CS and SWC were supported by the RK Mellon Institute for Pediatric Research, NIAID K22 AI123366, and NICHD R01 HD098428. PK is funded in part by the Bill and Melinda Gates Foundation (OPP1113682); NIAID 1U19AI109662, U19AI057229, and 5R01AI125197 grants; Department of Defense contracts W81XWH-18-1-0253 and W81XWH1910235; and the Ralph & Marian Falk Medical Research Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for collection of clinical data and patient serum through institutional review boards at the following institutions: Stanford University, University of Cincinnati, University of Pittsburgh and National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The SOMAscan data will be uploaded to GEO (Gene Expression Omnibus).
